Gossamer Bio, Inc. (GOSS)

Market Cap	190.35M
Revenue (ttm)	105.32M
Net Income (ttm)	-71.65M
Shares Out	226.60M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	835,731
Open	0.830
Previous Close	0.841
Day's Range	0.790 - 0.850
52-Week Range	0.499 - 1.600
Beta	1.89
Analysts	Strong Buy
Price Target	9.20 (+995.24%)
Earnings Date	Nov 7, 2024

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2019
• Employees: 135
• Stock Exchange: NASDAQ
• Ticker Symbol: GOSS
• Website: https://www.gossamerbio.com

Analyst Forecast

According to 5 analysts, the average rating for GOSS stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 995.24% from the latest price.

Price Target

$9.2

(995.24% upside)

Analyst Consensus: Strong Buy